Leadership Return And Clinical Strength Will Drive Long-Term Market Opportunity

Key Takeaways

• Increased early detection, demographic trends, and strategic partnerships are expanding the patient base and supporting sustained demand and revenue growth for Pulmonx.
  
• Clinical validation, reimbursement stability, and geographic expansion are driving broader adoption, improving margins, and strengthening Pulmonx's earnings stability and growth prospects.
  
• Heavy reliance on a limited product range, operational bottlenecks, and external uncertainties threaten Pulmonx's growth prospects, profitability, and resilience against shifting market dynamics.

Catalysts

A commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.

• Increased awareness and early detection through expanded lung cancer screening infrastructure and the adoption of tools like LungTraX Detect are driving more severe emphysema patients into the treatment funnel, setting the stage for future acceleration in revenue as procedure conversion rates improve.
  
• Strong global demographic trends-an aging population and rising prevalence of COPD-are continually expanding Pulmonx's total addressable market, which supports sustained long-term demand for Zephyr Valves and underpins ongoing revenue growth.
  
• The company's ecosystem-building approach, including partnerships (i.e., with Jaeger for pulmonary function testing), hospital integration, and direct-to-patient outreach, is unlocking alternative referral channels that will broaden patient access and could accelerate top-line growth and utilization rates over time.
  
• Continued clinical validation and positive real-world data for Zephyr Valves, combined with stable reimbursement, are poised to drive higher physician adoption and support further improvements in gross margins and earnings as scale is achieved and production costs are optimized.
  
• Geographic expansion, particularly success in international direct markets and the path toward commercialization in underpenetrated regions like Japan, will diversify revenue streams and improve earnings stability, mitigating risks tied to any single geographic region.

Pulmonx Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Pulmonx's revenue will grow by 8.8% annually over the next 3 years.
• Analysts are not forecasting that Pulmonx will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Pulmonx's profit margin will increase from -60.1% to the average US Medical Equipment industry of 11.8% in 3 years.
• If Pulmonx's profit margin were to converge on the industry average, you could expect earnings to reach $13.4 million (and earnings per share of $0.29) by about July 2029, up from -$53.2 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.5x on those 2029 earnings, up from -1.2x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.3x.
• Analysts expect the number of shares outstanding to grow by 3.66% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 9.09%, as per the Simply Wall St company report.

Risks

• Pulmonx's growth is currently constrained by bottlenecks in U.S. procedure volume, primarily due to operational pressures, slow conversion of new commercial initiatives, and healthcare provider capacity limitations-which could result in lower-than-expected revenue growth and continued net losses.
  
• The company's business remains highly reliant on the Zephyr Valve and related narrow product portfolio; delays in successful diversification (e.g., with AeriSeal or further expanding AI-enabled diagnostics) expose Pulmonx to risk from technological obsolescence or shifts in clinical practice, threatening long-term revenue streams and margin stability.
  
• Increasing dependence on complex workflows, multi-stakeholder engagement, and lengthy contracting cycles (particularly for new screening technologies like LungTrax Detect) could extend sales cycles, slow market penetration, and delay revenue realization, negatively affecting operating leverage and profitability.
  
• Intense international growth, especially in distributor-driven markets with expected second-half moderation and near-term uncertainty (such as low ordering from China), may lead to revenue volatility, particularly as Pulmonx has little short-term control over these external distributor dynamics.
  
• Persistently high operating expenses, increased R&D spending, and ongoing net losses-with only moderate guidance adjustments on cost and a relatively high cash burn rate-raise the risk that Pulmonx may struggle to achieve sustained profitability and positive earnings without a substantial and rapid acceleration in adoption and market penetration.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $3.4 for Pulmonx based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $5.0, and the most bearish reporting a price target of just $2.5.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $114.1 million, earnings will come to $13.4 million, and it would be trading on a PE ratio of 15.5x, assuming you use a discount rate of 9.1%.
• Given the current share price of $1.45, the analyst price target of $3.4 is 57.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.